Cargando…
CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer
INTRODUCTION: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). METHODS: Pretreatment fine-needle aspiration specimens from 45 patients with...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246190/ https://www.ncbi.nlm.nih.gov/pubmed/18086299 http://dx.doi.org/10.1186/bcr1836 |
_version_ | 1782150736501538816 |
---|---|
author | Esteva, Francisco J Wang, Jing Lin, Feng Mejia, Jaime A Yan, Kai Altundag, Kadri Valero, Vicente Buzdar, Aman U Hortobagyi, Gabriel N Symmans, W Fraser Pusztai, Lajos |
author_facet | Esteva, Francisco J Wang, Jing Lin, Feng Mejia, Jaime A Yan, Kai Altundag, Kadri Valero, Vicente Buzdar, Aman U Hortobagyi, Gabriel N Symmans, W Fraser Pusztai, Lajos |
author_sort | Esteva, Francisco J |
collection | PubMed |
description | INTRODUCTION: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). METHODS: Pretreatment fine-needle aspiration specimens from 45 patients with HER-2-overexpressing stage II to IIIA breast cancer were subjected to transcriptional profiling and examined for differential expression of various genes and gene sets. The primary endpoint for tumor response was pathologic complete response (pCR). Correlations between pCR and gene expression were sought. RESULTS: The overall pCR rate was 64%. Age, nuclear grade, tumor size, nodal status, quantitative expression of estrogen and HER-2 receptor mRNA, and HER-2 gene copy number showed no correlation with pCR. Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. CONCLUSION: CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer. |
format | Text |
id | pubmed-2246190 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2007 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-22461902008-02-20 CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer Esteva, Francisco J Wang, Jing Lin, Feng Mejia, Jaime A Yan, Kai Altundag, Kadri Valero, Vicente Buzdar, Aman U Hortobagyi, Gabriel N Symmans, W Fraser Pusztai, Lajos Breast Cancer Res Research Article INTRODUCTION: We performed gene expression analysis to identify molecular predictors of resistance to preoperative concomitant trastuzumab and paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide (T/FEC). METHODS: Pretreatment fine-needle aspiration specimens from 45 patients with HER-2-overexpressing stage II to IIIA breast cancer were subjected to transcriptional profiling and examined for differential expression of various genes and gene sets. The primary endpoint for tumor response was pathologic complete response (pCR). Correlations between pCR and gene expression were sought. RESULTS: The overall pCR rate was 64%. Age, nuclear grade, tumor size, nodal status, quantitative expression of estrogen and HER-2 receptor mRNA, and HER-2 gene copy number showed no correlation with pCR. Results of gene set enrichment analysis suggested that the lower expression of genes involved with CD40 signaling is associated with a greater risk of residual cancer after the preoperative chemotherapy that includes trastuzumab. CONCLUSION: CD40 signaling may play a role in determining response to trastuzumab-plus-T/FEC therapy in patients with HER-2-overexpressing breast cancer. BioMed Central 2007 2007-12-17 /pmc/articles/PMC2246190/ /pubmed/18086299 http://dx.doi.org/10.1186/bcr1836 Text en Copyright © 2007 Esteva et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an open access article distributed under the terms of the Creative Commons Attribution License ( (http://creativecommons.org/licenses/by/2.0) ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Esteva, Francisco J Wang, Jing Lin, Feng Mejia, Jaime A Yan, Kai Altundag, Kadri Valero, Vicente Buzdar, Aman U Hortobagyi, Gabriel N Symmans, W Fraser Pusztai, Lajos CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title_full | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title_fullStr | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title_full_unstemmed | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title_short | CD40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in HER-2-overexpressing breast cancer |
title_sort | cd40 signaling predicts response to preoperative trastuzumab and concomitant paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide in her-2-overexpressing breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246190/ https://www.ncbi.nlm.nih.gov/pubmed/18086299 http://dx.doi.org/10.1186/bcr1836 |
work_keys_str_mv | AT estevafranciscoj cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT wangjing cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT linfeng cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT mejiajaimea cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT yankai cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT altundagkadri cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT valerovicente cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT buzdaramanu cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT hortobagyigabrieln cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT symmanswfraser cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer AT pusztailajos cd40signalingpredictsresponsetopreoperativetrastuzumabandconcomitantpaclitaxelfollowedby5fluorouracilepirubicinandcyclophosphamideinher2overexpressingbreastcancer |